Target intelligence / Profile preview

UBE2V1 pseudogene 8 (UBE2V1P8)

Target
UBE2V1P8
Molecular classification
Other (pseudogene)
01

Overview

UBE2V1 pseudogene 8 (UBE2V1P8) is a non-protein coding pseudogene related to the UBE2V1 gene, a member of the ubiquitin-conjugating enzyme E2 family. UBE2V1P8 has no known protein product or biological function and is not classified as a therapeutic target. The UBE2V1 gene itself encodes a co-factor in non-canonical polyubiquitin chain synthesis and plays roles in cell signaling and disease, but its pseudogenes, including UBE2V1P8, are non-functional copies[5].

Other names
UBE2V1P8UBE2V1 Pseudogene 8

Beyond the preview

Go deeper on UBE2V1 pseudogene 8 (UBE2V1P8).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on UBE2V1 pseudogene 8 (UBE2V1P8).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call